Clinical use of high sensitivity C-reactive protein for the prediction of adverse cardiovascular events

被引：115

作者：

Torres, JL ^{[1
]}

Ridker, PM ^{[1
]}

机构：

[1] Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Cardiovasc Dis Prevent, Boston, MA 02215 USA

来源：

CURRENT OPINION IN CARDIOLOGY | 2003年 / 18卷 / 06期

关键词：

C-reactive protein; inflammation; myocardial infarction; prevention; statins; aspirin;

D O I：

10.1097/00001573-200311000-00008

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

High-sensitivity C-reactive protein evaluation has recently been endorsed by the Centers for Disease Control and Prevention and by the American Heart Association to be used in conjunction with lipid evaluation as part of global risk prediction. Emerging evidence further suggests that high-sensitivity C-reactive protein can be used to target pharmacologic and lifestyle interventions designed to prevent first as well as recurrent cardiovascular events.

引用

页码：471 / 478

页数：8

共 59 条

[31] Markers of inflammation and cardiovascular disease application to clinical and public health practice - A statement for healthcare professionals from the centers for disease control and prevention and the American Heart Association [J].

Pearson, TA ;

Mensah, GA ;

Alexander, RW ;

Anderson, JL ;

Cannon, RO ;

Criqui, M ;

Fadl, YY ;

Fortmann, SP ;

Hong, Y ;

Myers, GL ;

Rifai, N ;

Smith, SC ;

Taubert, K ;

Tracy, RP ;

Vinicor, F .

CIRCULATION, 2003, 107 (03) :499-511

[32] C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus [J].

Pradhan, AD ;

Manson, JE ;

Rifai, N ;

Buring, JE ;

Ridker, PM .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (03) :327-334

[33] Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease - Prospective analysis from the Women's Health Initiative observational study [J].

Pradhan, AD ;

Manson, JE ;

Rossouw, JE ;

Siscovick, DS ;

Mouton, CP ;

Rifai, N ;

Wallace, RB ;

Jackson, RD ;

Pettinger, MB ;

Ridker, PM .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (08) :980-987

[34] C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events [J].

Ridker, PM ;

Buring, JE ;

Cook, NR ;

Rifai, N .

CIRCULATION, 2003, 107 (03) :391-397

[35] Hormone replacement therapy and increased plasma concentration of C-reactive protein [J].

Ridker, PM ;

Hennekens, CH ;

Rifai, N ;

Buring, JE ;

Manson, JE .

CIRCULATION, 1999, 100 (07) :713-716

[36] High-sensitivity C-reactive protein - Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease [J].

Ridker, PM .

CIRCULATION, 2001, 103 (13) :1813-1818

[37] Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels [J].

Ridker, PM ;

Rifai, N ;

Pfeffer, MA ;

Sacks, FM ;

Moye, LA ;

Goldman, S ;

Flaker, GC ;

Braunwald, E .

CIRCULATION, 1998, 98 (09) :839-844

[38] Should statin therapy be considered for patients with elevated C-reactive protein? The need for a definitive clinical trial [J].

Ridker, PM .

EUROPEAN HEART JOURNAL, 2001, 22 (23) :2135-2137

[39] Clinical application of C-reactive protein for cardiovascular disease detection and prevention [J].

Ridker, PM .

CIRCULATION, 2003, 107 (03) :363-369

[40] Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events [J].

Ridker, PM ;

Rifai, N ;

Clearfield, M ;

Downs, JR ;

Weis, SE ;

Miles, JS ;

Gotto, AM .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (26) :1959-1965

← 1 2 3 4 5 6 →